Protagonist Therapeutics, Inc.
PTGX
Rankning i aktier
#2248
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aktiekurs
$140.05
Marknadsvärde
$9.06B
Förändring (1 dag)
1.49%
Förändring (1 år)
86.73%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Antal utestående aktier för Protagonist Therapeutics, Inc. (PTGX)
Antal utestående aktier per June 2026: 65.94M
Enligt de senaste finansiella rapporterna och aktiekursen för Protagonist Therapeutics, Inc. är det aktuella antalet utestående aktier 65.94M. I slutet av December 2023 hade företaget 56.76M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Protagonist Therapeutics, Inc. (PTGX) från 2014 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 65.94M | 7.10% |
| 2024 | 61.57M | 8.46% |
| 2023 | 56.76M | 15.74% |
| 2022 | 49.04M | 5.87% |
| 2021 | 46.32M | 34.67% |
| 2020 | 34.40M | 32.84% |
| 2019 | 25.89M | 15.78% |
| 2018 | 22.36M | 26.39% |
| 2017 | 17.69M | 172.15% |
| 2016 | 6.50M | 10.48% |
| 2015 | 5.88M | 0.00% |
| 2014 | 5.88M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 285.07% |
US
|
|
| 396.00M | 500.58% |
US
|
|
| 478.91M | 626.33% |
AU
|
|
| 62.19M | -5.69% |
NL
|
|
| - | - |
CH
|
